Suspension from Official Quotation - Annual Listing Fees

Key points

• Zelira Therapeutics Ltd's securities suspended for unpaid annual fees
• Suspension effective from 24 August 2026
• Other companies also affected by similar suspension
• Entities have until 28 August 2026 to pay fees to avoid removal from Official List

Full summary

ASX announced the suspension of securities from Official Quotation for Zelira Therapeutics Ltd and other entities due to the failure to pay annual listing fees by the deadline of 21 August 2026. Under Listing Rule 17.6, securities of companies that did not pay their annual listing fees by close of business on Friday, 21 August 2026, were suspended before the commencement of trading on Monday, 24 August 2026. Zelira Therapeutics Ltd is among the companies affected. Under Listing Rule 17.15, any entity that has not paid its annual listing fees as required by Listing Rule 16.5 by 5.00pm AEST on Friday, 28 August 2026, will be removed from the Official List with effect from the close of trading on Friday, 28 August 2026.